Home » About

Innovation Focused. Patient Driven.


Versartis was founded in 2008 with the goal of providing improved treatment options for patients with endocrine disorders who were not satisfied with currently available therapeutics


Versartis is headquartered in Menlo Park, Calif., and contributes to the Silicon Valley’s vibrant biotechnology landscape


XTEN is the proprietary technology used in the company’s lead product candidate, somavaratan (VRS-317), which is designed to prolong the molecule’s half-life and potentially improve therapeutic outcomes


Versartis currently has 50+ employees. Most employees have greater than 10 years of experience in top life sciences and biotechnology companies


Versartis’ lead candidate, somavaratan, is currently or has been under study at 100+ clinical trial sites

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry.

Our mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders.

We are focused on disorders that impact – often limit – patients in their daily lives, seeking to deliver therapies that represent improvements on previous standards-of-care. We believe that by minimizing the burden of GHD treatment for children and adults, we may enable them to better embrace their lives.

We are well-positioned to deliver a major innovation to the global GHD market with our most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.

Versartis is focused on rapidly progressing somavaratan through global clinical trials and, if they are successful, to eventual commercialization. Visit our clinical trials page to learn more.

We believe that smart partnerships better enable us to deliver on our mission, including collaborations with partners in science, academia, business and our local community. This is why we have partnered with Teijin Pharma Limited for the commercialization and further development efforts supporting somavaratan in Japan.

  • Schellenberger V, et al. (2009) Nature Biotechnology 27(12):1186-90.
  • Rosenfeld and Bakker. Endocr Pract. 2008;14(2)143-54.
  • Cutfield, et al. PloS One. 2011;6(1):e16223.
  • Versartis Long-Acting Growth Hormone in Children compared To Daily rhGH (VELOCITY). https://clinicaltrials.gov/ct2/show/NCT02339090
  • Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD. https://clinicaltrials.gov/ct2/show/NCT02719990
  • Cleland, et al. J Pharma Sci, August 2012, 101(8):2744-2754.